Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds

Abstract

The present invention relates to a composition comprising a catechin compound, ascorbic acid, proline and lysine. The present invention also relates to a method for treating neoplastic disease using a composition comprising a catechin compound, ascorbic acid, proline and lysine.

1 . A composition of biochemical substances comprising a catechin compound, an anti-oxidant, proline and lysine that is effective in inhibiting a matrix-metalloproteinase.  
     
     
         2 . The composition according to  claim 1 , wherein the catechin compound is selected from the group consisting of epicatechins, epigallocatechin, epicatechin gallate, and epigallocatechin gallate.  
     
     
         3 . The composition according to  claim 1 , wherein the catechin compound is epigallocatechin gallate.  
     
     
         4 . The composition according to  claim 1 , wherein the anti-oxidant is selected from the group consisting of ascorbic acid, tocopherols, tocotrienols, carotinoids, glutathione, alpha-lipoic acid, ubiquinols, bioflavonoids, and carnitine.  
     
     
         5 . The composition according to  claim 1 , wherein the anti-oxidant is ascorbic acid.  
     
     
         6 . The composition according to  claim 5 , wherein the ascorbic acid is selected from the group consisting of ascorbate precursors, ascorbate metabolites and an ascorbate salt.  
     
     
         7 . The composition according to  claim 1 , wherein the anti-oxidant further comprises a folic acid.  
     
     
         8 . The composition according to  claim 7 , wherein the folic acid is folate.  
     
     
         9 . The composition according to  claim 1 , wherein the composition further comprises a selenium.  
     
     
         10 . The composition according to  claim 9 , wherein the selenium is selected from the group consisting of selinite and methyl selinate.  
     
     
         11 . The composition according to  claim 1 , wherein the matrix-metalloproteinase is selected from the group consisting of matrix-metalloproteinase 1, matrix-metalloproteinase 2, matrix-metalloproteinase 3, matrix-metalloproteinase 4, matrix-metalloproteinase 5, matrix-metalloproteinase 6, matrix-metalloproteinase 7, matrix-metalloproteinase 8, matrix-metalloproteinase 9, matrix-metalloproteinase 10, matrix-metalloproteinase 11, matrix-metalloproteinase 12, and matrix-metalloproteinase 14.  
     
     
         12 . The composition according to  claim 1 , wherein the matrix-metalloproteinases is matrix-metalloproteinase 2.  
     
     
         13 . The composition according to  claim 1 , wherein the matrix-metalloproteinase is matrix-metalloproteinase 9.  
     
     
         14 . A method of treating human diseases associated with an elevated matrix-metalloproteinase activity by administering to a patient in need a composition of biochemical substances comprising a catechin compound, an anti-oxidant, proline and lysine that are effective in inhibiting a matrix-metalloproteinase.  
     
     
         15 . The method according to  claim 14 , wherein the catechin compound is selected from the group consisting of epicatechins, epigallocatechin, epicatechin gallate, and epigallocatechin gallate.  
     
     
         16 . The method according to  claim 14 , wherein the catechin compound is epigallocatechin gallate.  
     
     
         17 . The method according to  claim 14 , wherein the anti-oxidant is selected from the group consisting of ascorbic acid, tocopherols, tocotrienols, carotinoids, glutathione, alpha-lipoic acid, ubiquinols, bioflavonoids, and carnitine.  
     
     
         18 . The method according to  claim 14 , wherein the anti-oxidant is ascorbic acid.  
     
     
         19 . The method according to  claim 14 , wherein the ascorbic acid further comprises an ascorbate selected from the group consisting of ascorbate precursors, ascorbate metabolites and ascorbate salts.  
     
     
         20 . The method according to  claim 14 , wherein the anti-oxidant further comprises a folic acid.  
     
     
         21 . The method according to  claim 20 , wherein the folic acid is folate.  
     
     
         22 . The method according to  claim 14 , wherein the composition further comprises a selenium.  
     
     
         23 . The method according to  claim 14 , wherein the selenium is selected from the group consisting of selinite and methyl selinate.  
     
     
         24 . The method according to  claim 14 , wherein the human disease is selected from the group consisting of neoplastic diseases, inflammatory diseases, infectious diseases, cardiovascular diseases, degenerative diseases, neurological diseases and autoimmune diseases.  
     
     
         25 . A method of treating neoplastic diseases related to an excessive degradation of extracellular matrix comprising administering an effective amount of a composition comprising a catechin compound, an anti-oxidant, proline and lysine.  
     
     
         26 . The method according to  claim 25 , wherein the catechin is selected from the group consisting of epicatechins, epigallocatechin, epicatechin gallate, and epigallocatechin gallate.  
     
     
         27 . The method according to  claim 25 , wherein the catechin is epigallocatechin gallate.  
     
     
         28 . The method according to  claim 25 , wherein the anti-oxidant is selected from the group consisting of ascorbic acid, tocopherols, tocotrienols, carotinoids, glutathione, alpha-lipoic acid, ubiquinols, bioflavonoids, and carnitine.  
     
     
         29 . The method according to  claim 25 , wherein the anti-oxidant is ascorbic acid.  
     
     
         30 . The method according to  claim 25 , wherein the ascorbic acid further comprises ascorbate precursors, ascorbate metabolites and an ascorbate salt.  
     
     
         31 . The method according to  claim 25 , wherein the anti-oxidant further comprises a folic acid.  
     
     
         32 . The method according to  claim 31 , wherein the folic acid is folate.  
     
     
         33 . The method according to  claim 25 , wherein the composition further comprises a selenium.  
     
     
         34 . The method according to  claim 33 , wherein the selenium is selected from the group consisting of selinite and methyl selinate.  
     
     
         35 . A pharmacological preparation according to  claim 1 .  
     
     
         36 . A pharmaceutical preparation/s according to  claim 1 , where the pharmacological preparation is used for oral administration, parental administration or topical application.